Alzheimer's disease (AD) is a major public health issue facing the world's aging population;however, to date, there is no rapid and cost effective means for early diagnosis that is widely accessible. It has been suggested that a blood-based screening will become the first-step in the AD diagnostic process, although no such test currently exists. In our prior work through the Texas Alzheimer's Research &Care Consortium (TARCC), we created a serum-based screening algorithm that correctly classified 94% of those with and without AD. We then followed that work-up by creating a blood-based algorithm in the TARCC that worked across both serum and plasma that, when applied to the ADNI plasma samples, correctly classified 89% of those with and without AD in the entirely independent cohort. The long-term goal of this project is the validation of the our blood-based screening instrument for AD.
The specific aims of the current project are as follows:
Specific Aim 1 : To test the reliability and validity of our previously created blood-based screening algorithm, and Specific Aim 2: To validate our blood-based algorithms against other diagnostic modalities (i.e., neuropathological findings and CSF analyses). Multiplex serum- and plasma-based biomarker assays (using electrochemiluminescence) will be conducted on 1,100 samples from the TARCC and Mayo Clinic Jacksonville biobanks. The establishment of a blood-based screening instrument for AD will significantly change the field of geriatric medicine. Such a tool would fit into the existing medical infrastructure as a frontline population-based screening device where positive findings can be followed-up with clinical, imaging or CSF assessments. This overall approach will increase accessibility to standard care far beyond what can be offered by other methodologies. This approach will also provide a more rapid and cost-efficient means for screening into AD clinical trials.
Alzheimer's disease (AD) is a major public health issue facing the world's aging population;however, to date, there is no rapid and cost effective means for screening all those at risk for having the disease. The relevance of the current proposal is the establishment of a blood-based screener for AD that can be used and implemented as a frontline assessment device for clinical and research purposes. The establishment of a blood-based screener for AD would change the field of geriatric medicine and increase access to care globally.
|Robinson, Michelle D; Mishra, Ina; Deodhar, Sneha et al. (2017) Water T2 as an early, global and practical biomarker for metabolic syndrome: an observational cross-sectional study. J Transl Med 15:258|
|Johnson, Leigh A; Edwards, Melissa; Gamboa, Adriana et al. (2017) Depression, inflammation, and memory loss among Mexican Americans: analysis of the HABLE cohort. Int Psychogeriatr 29:1693-1699|
|Villarreal, Alcibiades E; O'Bryant, Sid E; Edwards, Melissa et al. (2016) Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. Neurodegener Dis Manag 6:203-13|
|O'Bryant, Sid E; Edwards, Melissa; Johnson, Leigh et al. (2016) A blood screening test for Alzheimer's disease. Alzheimers Dement (Amst) 3:83-90|
|Torrence, Nicole D; John, Samantha E; Gavett, Brandon E et al. (2016) An Empirical Comparison of Competing Factor Structures for the Repeatable Battery for the Assessment of Neuropsychological Status: A Project FRONTIER Study. Arch Clin Neuropsychol 31:88-96|
|O'Bryant, Sid E; Lista, Simone; Rissman, Robert A et al. (2016) Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimers Dement (Amst) 3:27-34|
|Chaudhari, K; Sumien, N; Johnson, L et al. (2016) Vitamin C Supplementation, APOE4 Genotype and Cognitive Functioning in a Rural-Dwelling Cohort. J Nutr Health Aging 20:841-844|
|Edwards, Melissa; Hall, James; Williams, Benjamin et al. (2016) Molecular markers of amnestic mild cognitive impairment among Mexican Americans. J Alzheimers Dis 49:221-8|
|Johnson, Leigh A; Gamboa, Adriana; Vintimilla, Raul et al. (2015) Comorbid Depression and Diabetes as a Risk for Mild Cognitive Impairment and Alzheimer's Disease in Elderly Mexican Americans. J Alzheimers Dis 47:129-36|
|O'Bryant, Sid E; Gupta, Veer; Henriksen, Kim et al. (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement 11:549-60|
Showing the most recent 10 out of 43 publications